Positive H1 Trading Update & Directorate Change

TRISTEL plc

("Tristel" or the "Company")

Positive H1 Trading Update

& Directorate Change

Tristel plc (AIM: TSTL), the manufacturer of infection prevention products, announces a positive trading update for the six months ended 31 December 2025. The board remains confident in delivering full year results in line with market expectations and the Company's own performance targets.

H1 Financial Highlights

· H1 revenues increased by 14% year-on-year

· Gross Margins maintained at 81%

· Adjusted EBITDA increased by 17%

· EBITDA margins of 28%, comfortably ahead of the 'at least 25% target'

· Continued progress in US with revenue growth in line with internal forecasts

· Tristel continues to be debt free and cash generative

· Cash balances at 31 December 2025 were £13.3m

The above highlights are based on unaudited figures and the Company intends to announce its interim results in early March.

Directorate Change

The Company also announces that Matt Sassone, Chief Executive Officer, has confirmed to the Board his decision to resign to take up a worldwide President role with a large US multinational, leading a significant global business. Matt will actively continue in post until the end of the financial year and has fully committed to continue leading the business through this period. The Board has already commenced the process to appoint a new CEO and is confident that there is sufficient management depth in the business to ensure that trading will not be impacted during the transition.

Commenting Matt Sassone, Chief Executive Officer, said:

"This is undoubtably one of the hardest business decisions I have ever had to make. The real strength of Tristel has never been one person, as the business has been carefully built on leaders at every level. Our strategy for growth is robust and remains unchanged, and the momentum we have is very real and can be seen already in the strong H1 performance. I am confident that the investment case of the business remains as compelling as ever.

"The opportunity I have to return to the US with my family, and to work in such a senior role with a large US multinational, is one which resonates with me on a personal level. It is with a very heavy heart that I will be leaving Tristel and I remain confident in our ability to take full advantage of the market opportunities, particularly in the US where there is clear evidence of traction and scale-up potential.

"I would like to thank the Board and the wider Tristel team for their support and hard work, and I would like to reassure investors that the business remains in a very strong position. Any new CEO coming into this role will see that this business has a well established platform to deliver significant growth."

Bruno Holthof, Chair of the Tristel Board, commented: "On behalf of the Company I would like to offer my thanks to Matt for his leadership, energy and contribution to Tristel since joining us in 2024. He has made a real impact in short period of time, and whilst we're sad to see him go, we respect his decision and wish him every success. We are confident in the strength of the leadership team and the wider organisation, and we remain confident that the strong momentum of the business will continue. The Board has already commenced the process of recruiting a new CEO, working carefully to find the right leader to build on the strong foundations already in place."

For further information please contact:

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the EU Market Abuse Regulation (596/2014) as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended. Upon the publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

About Tristel plc

Tristel plc is a global infection prevention company focussed on the manufacture and supply of products using its unique proprietary chlorine dioxide (ClO2) chemistry. The Company is a market leader in manual decontamination of medical devices, supplying hospitals under the Tristel brand, and under the Cache brand provides products for sporicidal surface disinfection, a more sustainable alternative to commonly used pre-wetted plastic wipes.

Tristel's head office and manufacturing facility is located in Snailwell, near Cambridge, and operates globally employing approximately 270 people across 16 subsidiaries selling into 40+ countries. The Company targets delivering double-digit revenue growth annually, an adjusted EBITDA margin of at least 25% and a continuing progressive year-on-year growth in dividends, underpinned by robust cash generation.

The Company has been listed on the London Stock Exchange's AIM market since 2005 (AIM: TSTL).

For more information about Tristel's product range please visit: https://tristel.com